Literature DB >> 230784

Latent herpes simplex virus infections in sensory ganglia of hairless mice prevented by acycloguanosine.

R J Klein, A E Friedman-Kien, E DeStefano.   

Abstract

Acycloguanosine (ACG) was able to prevent the fatal outcome of herpes simplex virus-induced skin infections of the lumbosacral or orofacila area in hairless mice. Topical ACG treatment was more effective than systemic treatment in preventing the evolution of skin lesions. Acute ganglionic infections in the trigeminal ganglia were prevented by ACG, and latent ganglionic infections did not become established when the ACG treatment was initiated 3 h after infection. Serum antibody titers were, on the average, eight times higher in mice which developed latent ganglionic infections after ACG treatment than in mice without evidence of herpes simplex virus latency in ganglia. Reinoculation of ACG-treated mice at a site different from that of the primary inoculation did not lead to the establishment of a second latent infection with the homologous virus type when a latent infection was already present. In mice without evidence of latent infection after the primary inoculation, a latent infection at the site of reinoculation became established in 25% of the animals.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 230784      PMCID: PMC352744          DOI: 10.1128/AAC.15.5.723

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

Review 1.  Herpetic keratitis. Proctor Lecture.

Authors:  H E Kaufman
Journal:  Invest Ophthalmol Vis Sci       Date:  1978-10       Impact factor: 4.799

2.  Effect of immunization on the development of latent ganglionic infection in mice challenged intravaginally with herpes simplex virus types 1 and 2.

Authors:  L V Asher; M A Walz; A L Notkins
Journal:  Am J Obstet Gynecol       Date:  1978-08-01       Impact factor: 8.661

3.  Efficacy of phosphonoacetic acid on herpes simplex virus infection of sensory ganglia.

Authors:  C R Wohlenberg; M A Walz; A L Notkins
Journal:  Infect Immun       Date:  1976-05       Impact factor: 3.441

4.  Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine.

Authors:  G B Elion; P A Furman; J A Fyfe; P de Miranda; L Beauchamp; H J Schaeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

5.  Latent herpes simplex virus in ganglia of mice after primary infection and reinoculation at a distant site.

Authors:  R J Klein; A E Friedman-Kien; E Brady
Journal:  Arch Virol       Date:  1978       Impact factor: 2.574

6.  Orofacial herpes simplex virus infection in hairless mice: latent virus in trigeminal ganglia after topical antiviral treatment.

Authors:  R J Klein; A E Friedman-Kien; P B Yellin
Journal:  Infect Immun       Date:  1978-04       Impact factor: 3.441

7.  9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group.

Authors:  H J Schaeffer; L Beauchamp; P de Miranda; G B Elion; D J Bauer; P Collins
Journal:  Nature       Date:  1978-04-13       Impact factor: 49.962

8.  Pathogenesis of latent herpes simplex virus infection of the trigeminal ganglion in guinea pigs: effects of age, passive immunization, and hydrocortisone.

Authors:  R B Tenser; G D Hsiung
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

9.  Immune response and latent infection after topical treatment of herpes simplex virus infection in hairless mice.

Authors:  R J Klein; A E Friedman-Kien; A A Fondak; E Buimovici-Klein
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

10.  Efficacy of herpes simplex virus type 1 immunization in protecting against acute and latent infection by herpes simplex virus type 2 in mice.

Authors:  R R McKendall
Journal:  Infect Immun       Date:  1977-05       Impact factor: 3.441

View more
  34 in total

1.  Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) in animals.

Authors:  M R Boyd; T H Bacon; D Sutton
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

2.  Immediate-early regulatory gene mutants define different stages in the establishment and reactivation of herpes simplex virus latency.

Authors:  D A Leib; D M Coen; C L Bogard; K A Hicks; D R Yager; D M Knipe; K L Tyler; P A Schaffer
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

3.  Evaluation of a peptidomimetic ribonucleotide reductase inhibitor with a murine model of herpes simplex virus type 1 ocular disease.

Authors:  C R Brandt; B Spencer; P Imesch; M Garneau; R Déziel
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

4.  Penetration of guinea pig skin by acyclovir in different vehicles and correlation with the efficacy of topical therapy of experimental cutaneous herpes simplex virus infection.

Authors:  S L Spruance; M B McKeough; J R Cardinal
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

5.  A randomized, double-blind, comparative trial comparing high- and standard-dose oral acyclovir for first-episode genital herpes infections.

Authors:  A Wald; J Benedetti; G Davis; M Remington; C Winter; L Corey
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

6.  Effects of topical applications of phosphonoacetate on colonization of mouse trigeminal ganglia with herpes simplex virus type 1.

Authors:  R J Klein; A E Friedman-Kien; L Kaley; E Brady
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

7.  Experimental skin infection with an acyclovir resistant herpes simplex virus mutant: response to antiviral treatment and protection against reinfection.

Authors:  R J Klein; E DeStefano; E Brady; A E Friedman-Kien
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

8.  Inhibition of herpesvirus multiplication in guinea pig skin by antiviral compounds.

Authors:  S Alenius
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

9.  Combined antiviral effect of interferon and acyclovir on herpes simplex virus types 1 and 2.

Authors:  T L Stanwick; R F Schinazi; D E Campbell; A J Nahmias
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

10.  Comparison of effects of famciclovir and valaciclovir on pathogenesis of herpes simplex virus type 2 in a murine infection model.

Authors:  A M Thackray; H J Field
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.